In colorectal cancer, the combined treatment of Trametinib and Everolimus, a MAPK/ERK pathway inhibitor and mTOR inhibitor, respectively, results in significant inhibition of tumor growth [211]. This evidence concerns the gene MTOR and neoplasm.